M&A Deal Summary

4basebio Acquires Expedeon Holdings

On May 9, 2016, 4basebio acquired life science company Expedeon Holdings

Acquisition Highlights
  • This is 4basebio’s 1st transaction in the Life Science sector.
  • This is 4basebio’s 1st transaction in the United Kingdom.

M&A Deal Summary

Date 2016-05-09
Target Expedeon Holdings
Sector Life Science
Buyer(s) 4basebio
Deal Type Add-on Acquisition

Target

Expedeon Holdings

Cambridgeshire, United Kingdom
Expedeon Holdings Ltd. develops, manufactures and commercializes proteomics reagents and tools. Company Protein Discovery line of sample preparation and protein fractionation products for Mass-Spectrometry is at the cutting edge of proteomic analysis.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

4basebio

Cambridge, United Kingdom

Category Company
Founded 2008
Sector Life Science
Employees110
Revenue 1M GBP (2023)
DESCRIPTION

4basebio is a development of novel, superior tools for molecular biology that play key roles in changing the way genomic and proteomic research is done today. Demand for such tools is high in the fast-growing DNA and protein analysis markets. SYGNIS’ polymerases enable a wide range of applications for DNA amplification, repair, sequencing, detection, and modification of genetic targets of clinical value. The company is thus ideally suited to play a major part in the global effort to discover the genetic markers of disease, and their cost-effective detection, in individual patients to deliver optimized treatments. 4basebio was founded in 2008 and is headquartered in Cambridge, England.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2016 M&A 1 of 1